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Background: Breast, colorectal, ovarian, and endometrial cancers constitute approximately 30% of newly diagnosed cancer
cases in Switzerland, affecting more than 12,000 individuals annually. Hundreds of these patients are likely to carry germline
pathogenic variants associated with hereditary breast ovarian cancer (HBOC) or Lynch syndrome (LS). Genetic services (counseling
and testing) for hereditary susceptibility to cancer can prevent many cancer diagnoses and deaths through early identification and
risk management.
Objective: Cascade screening is the systematic identification and testing of relatives of a known mutation carrier. It determines
whether asymptomatic relatives also carry the known variant, needing management options to reduce future harmful outcomes.
Specific aims of the CASCADE study are to (1) survey index cases with HBOC or LS from clinic-based genetic testing records
and determine their current cancer status and surveillance practices, needs for coordination of medical care, psychosocial needs,
patient-provider and patient-family communication, quality of life, and willingness to serve as advocates for cancer genetic
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services to blood relatives, (2) survey first- and second-degree relatives and first-cousins identified from pedigrees or family
history records of HBOC and LS index cases and determine their current cancer and mutation status, cancer surveillance practices,
needs for coordination of medical care, barriers and facilitators to using cancer genetic services, psychosocial needs, patient-provider
and patient-family communication, quality of life, and willingness to participate in a study designed to increase use of cancer
genetic services, and (3) explore the influence of patient-provider communication about genetic cancer risk on patient-family
communication and the acceptability of a family-based communication, coping, and decision support intervention with focus
group(s) of mutation carriers and relatives.
Methods: CASCADE is a longitudinal study using surveys (online or paper/pencil) and focus groups, designed to elicit factors
that enhance cascade genetic testing for HBOC and LS in Switzerland. Repeated observations are the optimal way for assessing
these outcomes. Focus groups will examine barriers in patient-provider and patient-family communication, and the acceptability
of a family-based communication, coping, and decision-support intervention. The survey will be developed in English, translated
into three languages (German, French, and Italian), and back-translated into English, except for scales with validated versions in
these languages.
Results: Descriptive analyses will include calculating means, standard deviations, frequencies, and percentages of variables
and participant descriptors. Bivariate analyses (Pearson correlations, chi-square test for differences in proportions, and t test for
differences in means) will assess associations between demographics and clinical characteristics. Regression analyses will
incorporate generalized estimating equations for pairing index cases with their relatives and explore whether predictors are in
direct, mediating, or moderating relationship to an outcome. Focus group data will be transcribed verbatim and analyzed for
common themes.
Conclusions: Robust evidence from basic science and descriptive population-based studies in Switzerland support the necessity
of cascade screening for genetic predisposition to HBOC and LS. CASCADE is designed to address translation of this knowledge
into public health interventions.
Trial Registration: ClinicalTrials.gov NCT03124212; https://clinicaltrials.gov/ct2/show/NCT03124212 (Archived by WebCite
at http://www.webcitation.org/6tKZnNDBt)
(JMIR Res Protoc 2017;6(9):e184)   doi:10.2196/resprot.8138
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Introduction
Breast, colorectal, ovarian, and endometrial cancers constitute
approximately 30% of newly diagnosed cancer cases in
Switzerland, affecting more than 12,000 individuals annually
[1]. About 2%-15% of incident cases are associated with known
hereditary cancer syndromes. Several hundred Swiss patients
diagnosed with any of these cancers are likely to carry known
pathogenic germline variants [2]. Approximately 5-10% of
breast cancer cases and 10%-15% of epithelial ovarian cancer
cases develop due to single gene mutations that are passed down
in the family, such as the breast cancer 1 (BRCA1) and breast
cancer 2 (BRCA2) genes [3,4]. Germline BRCA mutations are
associated with most hereditary breast and ovarian cancer
(HBOC) cases. Women with BRCA mutations have a 55%-70%
risk of breast cancer and 17%-59% risk of ovarian cancer by
age 70, while the corresponding lifetime risks in the general
population are 12% and 1.3%, respectively [5-7]. HBOC cases
have an increased risk of cancer at a younger age, often before
recommendations for routine screening apply [8,9]. The
prevalence of BRCA mutations varies considerably among ethnic
groups and geographical areas. In Caucasian populations, the
prevalence of BRCA pathogenic variants is estimated at 1:400
to 1:500, whereas the frequency of three founder mutations in
the Ashkenazi Jewish population is 1:40 [10-12]. About 21%
of Swiss breast cancer patients are diagnosed younger than 50
years old, which may indicate genetic susceptibility [13,14].
Lynch syndrome (LS), previously known as hereditary
nonpolyposis colorectal cancer, is an inherited disorder,
associated with 22%-74% lifetime risk for colorectal cancer,
14%-71% risk for endometrial cancer, 3%-22% risk for ovarian
cancer, up to 13% risk for gastric cancer, and up to 25% risk
for urothelial cancer [15]. LS accounts for about 2%-5% of
colorectal cancer and endometrial cancer burden, as well as
increased risk for several other malignancies including gastric,
ovarian, small bowel, urinary and biliary tract, pancreatic, and
sebaceous gland tumors [16]. Individuals with LS have a
10%-74% risk of colorectal cancer, and a 14%-71% risk of
endometrial cancer by age 70, while the corresponding rates in
the general population are 5.5% and 2.7%, respectively [17,18].
A hallmark of LS is early age of onset, usually before the age
of 50 at which recommendations for routine screening apply
[15,19]. Most LS-related tumors are characterized by a high
level of microsatellite instability (MSI-H), which is distinctive
of cancers with a defective DNA mismatch repair (MMR)
mechanism [20]. Diagnosis of LS involves a sequential process
including prescreening with MSI testing and
immunohistochemistry analysis to determine expression of the
main MMR proteins (MLH1, MSH2, MSH6, PMS2) in tumor
tissues. Additional MLH1 promoter methylation testing
eliminates the possibility of loss of MLH1 expression due to
epigenetic mechanisms or identification of a somatic BRAF
pathogenic variant (c.1799T>A/p.V600E). In the case of
pathological prescreening results, germline analyses of two or
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more MMR genes (MLH1/PMS2 and/or MSH2/MSH6) and
search for EPCAM deletions confirm the diagnosis. Germline
mutations in the MLH1 and MSH2 genes account for up to 90%
of LS cases, whereas MSH6 and PMS2 mutations account for
most of the remaining cases [21]. The Amsterdam Criteria II
and Revised Bethesda Guidelines are used in clinical practice
for identifying individuals concerned about LS [22]. These
guidelines are not sensitive enough and may miss up to 30% of
LS cases [23]. Even if the population prevalence of LS is
estimated at 1:440 [24], LS is vastly underdiagnosed compared
to HBOC.
Germline mutations connected to HBOC and LS are inherited
in an autosomal dominant manner. De novo mutations are rare
in these syndromes. For every identified mutation carrier, there
are multiple family members who may carry the same mutation.
First- and second-degree relatives and first cousins of known
carriers have 50%, 25%, and 12.5% probability for inheriting
the respective cancer predisposition. The availability of cancer
genetic services (counseling and testing) for HBOC and LS is
a significant milestone for effective cancer prevention and
control [25]. When a pathogenic variant is identified, relatives
can be tested with 100% accuracy [26]. Genetic counseling can
educate patients and cancer-free individuals about cancer risk
and management options according to mutation status.
Physicians’ attitudes [27] and coverage of cost of tests and gene
panels by health insurance influence whether genetic testing is
performed or not [28].
A Swiss study reported that about 11% of all breast cancer
patients and 25% of those with a strong family history used
genetic services [29]. These figures are lower for LS-related
colorectal and endometrial cancer patients, suggesting that many
Swiss mutation carriers and their family members may not
benefit from advances in health care technology and medical
diagnostics. HBOC and LS patients are at an increased risk of
secondary cancers and can benefit from intensive surveillance,
pharmacoprevention, or prophylactic surgery. Prophylactic
surgery such as mastectomy, bilateral salpingo-oophorectomy,
and hysterectomy should be discussed with women affected
with HBOC or LS [30]. Subtotal colectomy can be considered
for LS patients with colorectal cancer [18]. Family members
who test positive benefit from high-risk management care
starting at age 25-30, or 10 years before the earliest age of breast
cancer onset in the family. This care can include annual breast
magnetic resonance imaging, mammograms, pelvic ultrasound
for women (HBOC) [31], and annual colonoscopy starting at
age 20-25, or 2-5 years before the earliest age of colorectal
cancer onset in the family, whichever comes first (LS) [15,18].
Implementing clinical recommendations and providing
high-quality surveillance to patients during survivorship requires
excellent coordination of health care services provided in
high-risk clinics [32-35].
Mutation carriers identified through complete genetic analyses
are asked to communicate test results to relatives and encourage
them to use genetic services. This process is highly variable
from family to family, with less than 40% of high-risk relatives
using genetic services, suggesting a lack of effective
communication [36,37]. Lack of understanding of genetic
information combined with family conflicts most likely inhibits
disclosure of test results to relatives [38,39]. In Switzerland,
the Federal Act on Human Genetic Testing (HGTA) is the legal
regulation that directly applies to the clinical practice of genetic
analysis. HGTA states that a physician is not allowed to disclose
genetic test results to anyone except the tested individual or
their legal representative. Results can be disclosed to family
members, spouses, or partners only with the explicit consent of
the tested individual. If the tested individual refuses to disclose
this information, if they are deceased, have disappeared, or are
unable to consent in the absence of an authorized delegate, the
physician can seek help from the expert commission on
professional confidentiality. The physician may apply to the
appropriate cantonal authority to be released from the duty of
professional secrecy if protecting the overriding interests of the
family members, spouse, or partner requires that they receive
this information. Cantonal authorities may also request an
opinion from the Expert Commission for Human Genetic Testing
[40]. Interventions designed to facilitate patient-provider and
patient-family communication can enhance understanding of
genetic information and facilitate the disclosure of test results
from carriers to relatives and can contribute to more effective
management of hereditary cancer. Several such interventions
have been developed and tested in the United States [41-51] but
should be adapted before they can be implemented in
Switzerland, due to cultural and possibly legal differences.
Cascade screening is the sequential process of identifying and
testing blood relatives of a known mutation carrier to determine
if additional individuals carry the pathogenic variant, and
proposing preventive and other clinical management options to
reduce morbidity and mortality [52]. Cascade screening also
reassures non-carrier relatives and excludes them from intensive
surveillance, making it cost-effective and contributing to
personalized medicine [53]. The Centers for Disease Control
and Prevention, Office for Public Health Genomics issued
evidence-based recommendations justifying genetic testing in
affected individuals and relatives when there is a known family
history of HBOC or other BRCA-related cancers, LS-related
colorectal cancer, or familial hypercholesterolemia (FH). These
are Tier 1 genetic conditions suitable to promoting translation
of scientific breakthroughs in genetics to public health [54].
There are currently no systematic efforts to apply cascade
screening for Tier 1 genetic conditions among the general
population in Europe apart from the Netherlands, which
successfully implemented a cascade screening program for FH.
The implementation of this pioneering public health program
helped identify more than 28,000 asymptomatic cases [55] and
provides proof-of-concept that cascade screening can be applied
in other settings [56].
Robust evidence from basic science and descriptive
population-based studies in Switzerland support the necessity
of cascade screening for HBOC and LS [57-67]. However, there
are currently no interventions to translate this knowledge into
public health. Researchers know little about the cancer status
and surveillance behaviors of mutation carriers and their
relatives, and their needs for psychosocial, patient-provider,
and family communication support. This is especially important
over time, as little is known about decisional regret associated
with genetic testing, communication, and support after the
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pathogenic variant has been identified in some family members
but not in others, as well as impact on quality of life. A better
understanding is needed of the overall response of the Swiss
health care system to mutation carriers’ needs for long-term
coordination of cancer surveillance and prevention. Finally,
there are no interventions culturally tailored for Swiss families
and designed to enhance patient-provider and patient-family
communication, coping, and provide decisional support.
Establishing a registry with families harboring germline
pathogenic variants associated with HBOC and LS and the
collection of cancer surveillance and psychosocial data over
time will greatly assist in finding sustainable solutions and
developing cutting-edge interventions that optimize the health
care system. However, establishing cascade screening for HBOC
and LS and promoting interventions for communicating
hereditary cancer risks pose several challenges at the medical
and social level, requiring interprofessional collaboration with
stakeholders from basic research, the health care system, and
social science. In response to this challenge, the Swiss Cancer
Genetic Predisposition Cascade Screening Consortium was
assembled in 2015 with stakeholders from various disciplines
(ie, basic science, epidemiology, medicine, nursing, psychology,
public health, and sociology) to conduct the CASCADE study
and examine the feasibility of establishing a family-based
registry and a cohort with HBOC and LS mutation-harboring
families.
The specific aims of the CASCADE study are to (1) survey
index cases with HBOC or LS from clinic-based genetic testing
records and determine their current cancer status and
surveillance practices, needs for coordination of medical care,
psychosocial needs, patient-provider and patient-family
communication, quality of life, and willingness to serve as
advocates for cancer genetic services to blood relatives, (2)
survey blood relatives identified from pedigrees or family history
records of HBOC and LS index cases and determine their current
cancer and mutation status, cancer surveillance practices, needs
for coordination of medical care, barriers and facilitators to
using cancer genetic services, psychosocial needs,
patient-provider and patient-family communication, quality of
life, and willingness to participate in a study designed to increase
use of cancer genetic services, and (3) explore the influence of
patient-provider communication about genetic cancer risk on
patient-family communication and the acceptability of a
family-based communication, coping, and decision support




CASCADE is a longitudinal study using surveys and focus
groups, designed to elicit factors that enhance cascade genetic
testing for HBOC and LS in Switzerland. The CASCADE study
will contact known mutation carriers for HBOC and LS and
systematically identify and contact their relatives to determine
if they have had genetic testing, if they also carry the pathogenic
variant, and how they manage their risk for hereditary cancer.
Repeated observations are the optimal way for assessing these
outcomes. The study will also use focus groups to examine the
acceptability of a family communication, coping, and decision
support intervention (Phase I). Table 1 presents a detailed
description of assessments conducted for the study. The study
protocol has been approved by the local ethics committee, while
approval from ethics committees in other cantons is underway.
The study will be carried out according to principles described
in the Declaration of Helsinki and applicable Swiss laws and
Swiss regulatory authority requirements.
Setting
This multicenter study involves contributions from oncology
and genetic testing centers from three linguistic regions of
Switzerland (German-, French-, and Italian-speaking). Medical
directors of clinical sites are either co-principal investigators
(co-PIs) or site co-investigators and will oversee recruitment
procedures according to the study protocol. The PI will oversee
the scientific integrity of the study, including recruitment, data
collection, and data analyses. These findings will be compiled
and communicated to clinical sites.
Sample and Sample Size
The CASCADE study targets individuals who have been
identified through genetic testing as carrying a pathogenic
germline variant associated either with HBOC or LS and their
relatives (first- and second-degree, and first cousins). Textbox
1 describes applicable inclusion and exclusion criteria. Index
cases include male and female cancer patients and cancer-free
individuals. Cancer risk associated with HBOC and LS does
not apply to children, thus, the study will include only adults
(≥18 years old). Decisions to undergo genetic testing for these
conditions are made by adults deemed competent to provide
informed consent and should be undertaken after individuals
participate in consultation regarding the benefits and drawbacks
of genetic testing. Vulnerable participants (eg, those living in
nursing homes) will be excluded because they may not be able
to consent to genetic testing or follow recommended cancer
surveillance or preventive measures. Critically ill patients will
be excluded from recruiting relatives and from focus groups to
avoid increasing subject burden.
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Table 1. Flow of assessments for the CASCADE study.
DataTasks/ProceduresPhase and steps
Selection of eligible index cases
No identifiable data for index cases are shared with
the PI.
Each clinical site provides the principal investigator
(PI) with a list of the family identifications (IDs)
determined by the clinical site as harboring a
Random selection of families
pathogenic germline variant. The PI randomly se-
lects 35% of family IDs from the list with computer-
generated numbers. The number of selected family
IDs at each site is based on total number of family
IDs at the clinical site and stratification for repre-
sentative sampling.
Clinical sites collect minimal data (except identifi-
able data) for all index cases, regardless of whether
Through pedigrees and family history records, each
site coordinator identifies index cases (1st family
Identification of eligible index cases
they can be reached or not. Minimum data includemember to be identified as a carrier of a germline
gender, age, mutation, cancer type, age at diagnosis,pathogenic variant) and determines whether they
stage, age tested, alive, place of residence, preferred
language.
can be contacted (ie, alive and living in Switzer-
land). If an index case cannot be contacted, site
coordinators identify 1st degree relatives who carry
the familial pathogenic variant, randomly select one
of them (computer-generated numbers), and deter-
mine whether they can be contacted. The process
is repeated until an eligible mutation carrier is
identified that can initiate cascade screening in the
family.
Recruitment of eligible index cases
Unique identification coding scheme enabling
identifying index cases, site they were recruited
The medical director of each clinical site (co-PI or
site co-investigator) and the site coordinator mail
Recruitment package to index cases
from, and type of hereditary cancer syndrome
(HBOC or LS).
Dates recruitment packages were sent to physicians,
dates the response from Index cases was received,
and recruitment attempts made.
recruitment packages to index cases. If the index
case did not receive genetic counseling at the testing
site, then the recruitment package is sent to the re-
ferring physician who is asked to pass it on. Three
attempts will be made to contact index cases. The
medical director will inform treating oncologists
about the participation of index cases.
Identifiable information for index cases accepting
participation is passed on from site coordinators to
the PI.
Response rate from index cases, acceptance to par-
ticipate in various stages of the CASCADE study,
The site coordinator receives the informed consent
or participation refusal form from index cases. In-
dex cases accepting participation receive the CAS-
CADE survey in their preferred language and for-
mat (paper/pencil or online) from the PI. The PI
creates a coding key for identifying participants and
Engagement of index cases in the
CASCADE study
reasons for nonparticipation and preferred language
and format for survey.the Clinical Trials Unit creates a coding key for
variables assessed in the CASCADE survey.
Assessment of data quality in each format (eg, per-
cent missing data, outliers). Assessment of instru-
The PI and the data management team receive the
completed survey from index cases either in pa-
per/pencil or online.
Survey from index cases
ment reliability (Cronbach alpha and principal
component analysis). Number of eligible relatives.
Number of eligible relatives the index case is will-
ing to invite. Characteristics of relatives reported
by the index case. CASCADE study outcomes.
Recruitment of eligible blood relatives
Number of relatives and degree of relationship to
the index case (1st or 2nd degree relative, or 1st
cousin).
Based on index cases’ response to the CASCADE
survey, the PI identifies eligible blood relatives the
index case is willing to invite. Information about
relatives is cross-referenced with pedigrees and
family history information from clinical sites.
Identification of eligible relatives
Unique identification coding scheme enabling
matching members of the same family.
The PI prepares recruitment packages for relatives
and a personalized letter for each index case, ex-
plaining the recruitment process and asking them
to pass on recruitment packages to relatives.
Recruitment package to eligible rela-
tives
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Response rate from relatives, acceptance to partici-
pate in various arms of the CASCADE study, rea-
sons for nonparticipation and preferred language
and format for survey completion.
The PI receives informed consents or participation
refusal forms from relatives. Relatives accepting
participation receive the CASCADE survey in their
preferred language and format (paper/pencil or on-
line).
Engagement of eligible relatives in the
CASCADE study
Assessment of data quality in each format (eg, per-
cent missing data, outliers). Assessment of instru-
ment reliability (Cronbach alpha and principal
component analysis). Number of eligible relatives
willing to invite.
CASCADE study outcomes.
The PI and the data manager receive the completed




Characteristics of index cases invited in the focus
groups (preferred language, gender, mutation, type
of cancer).
Characteristics of families invited in the focus
groups (level of support and communication).
A purposeful sample of index cases and relatives
accepting participation in focus groups will be se-
lected by the qualitative methodologist and the PI.
Selection of index cases and relatives
Acceptance rate.The PI in collaboration with the qualitative
methodologist will send invitation letters initially
to index cases and then to families selected for the
focus groups.
Invitation letters for focus groups
Narrative data from focus groups.Focus groups are organized and completed under
the auspices of the qualitative methodologist.
Focus groups
Textbox 1. Characteristics of the target populations.
Inclusion criteria
• Living carriers of germline pathogenic variants associated with HBOC and LS, and their relatives (1st and 2nd degree, and 1st cousins)
• Have at least one living blood relative
• Both genders
• Age ≥18 years old
• Mentally/physically able to provide informed consent
• Cancer patients and cancer-free individuals
• Can read/speak German or French or Italian or English
• Currently living in Switzerland
Exclusion criteria
• Carriers of unclassified genetic variants in BRCA1, BRCA2 or MLH1, MSH2, MSH6, PMS2, EPCAM genes
• Currently not living in Switzerland
• Critically ill patients not able to complete the survey
• Not able to provide an informed consent
• Institutionalized (eg, nursing homes) or incarcerated
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Figure 1. Expected recruitment of index cases.
Estimates of sample size are based on the PI’s experience,
consultations with medical directors of clinical sites, and
assuming average prevalence rates of 5% for hereditary breast
cancer and 2-5% for hereditary colorectal cancer (the two most
common manifestations of HBOC and LS), respectively.
Assuming that is feasible to recruit 10% of mutation carriers
from each participating clinic, 300 index cases will be targeted
for inclusion within 12 months. It is expected that around 70%
of approached index cases will accept participation, meaning
that 495 index cases need to be approached to reach 305. It is
estimated that from each index case we will identify 2.5
relatives. Assuming a response rate of 50% among relatives,
we expect to recruit approximately 381 relatives. Figure 1
presents the CONSORT [68] diagram for recruitment of
expected index cases and relatives.
Recruitment Procedures for Index Cases
Participating Swiss clinical sites will record the total number
of mutation-harboring families for HBOC or LS. A dedicated
staff person at each clinical site, the site coordinator, will
identify eligible index cases (ie, first person in the family
identified as carrying a germline pathogenic variant associated
with HBOC or LS), determine whether they can be contacted
or not, and initiate and monitor the recruitment process.
Selection of mutation-harboring families from each clinical site
will involve the following steps:
1. Each site creates a list with IDs (eg, 001…, 350)
corresponding to each index case and a family with a
pathogenic variant.
2. The ID list is sent to the PI, who selects approximately 35%
of cases with the assistance of a computer-generated random
list. Identifiable information is not released until the index
case accepts participation through signing an informed
consent form.
3. Site coordinators retrieve the medical charts of selected
index cases and decide whether the cases can be contacted
by determining living status and residence.
4. If the index case is not available, then site coordinators
identify first-degree relatives, who have also been identified
through genetic testing as carriers of the familial pathogenic
variant, and randomly (computer-generated list) select one
of them.
5. Steps 3 and 4 are repeated until an index case who can be
the initial contact person for the family is identified. If this
process yields no results, the next family is selected.
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6. All information obtained from each step is recorded,
including minimum information for index cases. Minimum
information includes demographics (age, gender), clinical
history (tumor type, age at diagnosis, stage), and genetic
testing results (including MSI and IHC tumor testing for
LS patients) and is obtained from medical records. Index
cases are recruited to the CASCADE study by the medical
director of the respective site.
Index cases will be mailed an information letter, two copies of
the informed consent form, two copies of a participation refusal
form, and a stamped self-addressed envelope to return their
response to the clinical site. Index cases will be informed about
the objectives of the CASCADE study, participation
requirements, the study plan, confidentiality, and associated
risk and benefits through the informed consent form, which
explicitly requires their agreement to (1) complete the
CASCADE survey, (2) contact one or more of their blood
relatives for the study, (3) be contacted once a year for 5 years
and provide updated information about their health, and (4)
participate alone or with a blood relative in a focus group. Index
cases can participate in all or in some of the above study steps.
The information letter explains that the minimum requirement
for taking part in the CASCADE study is to complete the
self-administered survey once. The refusal form asks
nonparticipating index cases the reason for their refusal; this
information is necessary for the validity of the study.
Site coordinators will determine whether the identified index
case can be contacted or not by investigating whether they are
alive and whether they live in Switzerland through hospital and
civil records. If the recruitment package is returned undelivered,
additional address verification methods will be used to locate
a new residence. If the index case cannot be contacted a priori,
coordinators will determine whether a first-degree relative can
be the new index case for the family. Three attempts will be
made to contact index cases for each family. If the study receives
no response 6 weeks after the third attempt, a new family will
be selected to preserve required sample size. Index cases will
be recruited to the CASCADE study on a consecutive ongoing
basis. Site coordinators will review pedigrees and family history
of index cases who accept participation to extract demographic
and medical information and to record all blood relatives (first-
and second-degree relatives and first cousins). Index cases will
be asked to complete a self-administered survey.
When an index case has not received genetic counseling at the
participating center, the invitation package for the CASCADE
study will be sent by the referring physician. This is necessary
because some clinical sites perform only genetic testing and the
referring physician is considered the medical person who has
direct knowledge of index case’s genetic testing results. Site
coordinators and the PI will keep track of the recruitment
process. Referring physicians will make three recruitment
attempts by mailing a new invitation package every 6 weeks if
the index case does not respond to the invitation (either
positively or negatively). Contact information (address,
telephone, email) of the PI and the medical director will be
provided in the information letter, so that index cases can request
further information about the study at any point. A signed
informed consent will be requested prior to index case’s
enrollment as a prerequisite for engagement in the CASCADE
study.
Recruitment Procedures for Relatives
In order to alleviate ethical concerns associated with contacting
blood relatives (ie, first- and second-degree relatives, and first
cousins) without their explicit consent, the CASCADE study
will approach them through index cases and will approach only
relatives the index case is willing to contact. This recruitment
method has been used in previous family-based studies with
very good recruitment outcomes [69,70]. Index cases will be
mailed recruitment packages to pass on to their relatives,
including an information letter, two copies of the informed
consent form, two copies of the participation refusal form, and
a stamped self-addressed envelope for relatives to return their
response to the PI. Relatives’ identifiable information will not
be released to the PI. By returning a signed informed consent,
the relative indicates willingness to participate and releases their
identifiable information to the PI. Once this information is
available, a recruiter will contact them to ascertain eligibility.
If relatives do not respond after 6 weeks, the PI will contact the
index case asking them to pass on a reminder letter to the
nonresponding relative. If this effort yields no response, there
will be no further attempts to contact the relative. Relatives
agreeing to participate will receive a similar survey as the index
case, asking if they are willing to (1) invite additional relatives
to the CASCADE study, (2) be contacted once a year for 5 years
and provide updated information about their health, and (3)
participate alone or with a blood relative in a focus group.
Relatives can also participate in all or some of the above study
steps.
Recruitment Procedures for Focus Groups
Two series of focus groups will be organized to explore the (1)
difficulties associated with patient-provider communication
regarding genetic cancer risk, (2) difficulties associated with
patient-family communication regarding the pathogenic
mutation, (3) mutual influence of patient-provider and
patient-family communication, and (4) acceptability of a
family-based intervention designed to enhance communication,
coping, and decision making for genetic testing. A purposeful
sample of index cases and relatives will be selected from
individuals who agreed to participate in focus groups. The
sampling method will be based on the expertise of the qualitative
methodologist from interviews with Swiss BRCA carriers
[32,33,71] and the PI’s experience conducting focus groups
with US BRCA families. Segmentation strategy will guide
sampling methods and the composition of the focus groups.
Each focus group will be relatively homogeneous, while the
full set will include several potentially distinct perspectives
[72]. Focus groups will include 5-10 participants. Male and
female cancer patients and cancer-free individuals will be
selected to represent HBOC and LS.
It is expected that data saturation will be reached with 6-10
focus groups including about 30-60 carriers and 30-60 relatives.
The first series of focus groups will include only mutation
carriers stratified according to level of family communication
(high, intermediate, low). These focus groups will explore the
difficulties in patient-provider and patient-family
JMIR Res Protoc 2017 | vol. 6 | iss. 9 | e184 | p.8http://www.researchprotocols.org/2017/9/e184/
(page number not for citation purposes)
Katapodi et alJMIR RESEARCH PROTOCOLS
XSL•FO
RenderX
communication, and the interrelatedness of these two types of
communication. The second series of focus groups will include
carriers and relatives and will explore the acceptability of an
intervention designed to facilitate communication of test results
among family members, helpful coping mechanisms, and
decision making for genetic testing. Two sampling methods are
envisioned. One method involves several members of the same
family who can be invited together; the other involves 3-4 family
pairs consisting of one carrier and one relative, which will be
homogeneous in terms of gender, health status, etc. The
sampling method of the second series of focus groups will be
informed by responses to the CASCADE survey and findings
from the first series of focus groups.
Data Collection and Data Management
The CASCADE survey will be developed in English, translated
into three languages (German, French, and Italian), and
back-translated into English by professional translators, except
for scales with validated versions in these languages (eg, 12-Item
Short Form Health Survey [SF-12]). Discrepancies will be
resolved by the PI with the collaboration of the translators and
the co-investigators. Index cases and relatives will be given the
choice to complete the CASCADE survey either as paper/pencil
or using an online platform. The content of the paper/pencil and
online survey are identical. Participants who choose to complete
the survey online will receive an access code and will be
instructed how to log into a secure Web platform. If a survey
is missing important information (eg, number of relatives the
index case is willing to contact), research personnel will contact
participants to ascertain it.
No identifying information, such as name and address, is
collected with paper/pencil or online surveys. Each index case
is given a code; for example, G001-IC stands for an index case
selected from the Geneva clinic with the family study code 001.
Relatives recruited from this index case will be coded G001-R1,
G001-R2, etc, to establish the link between family members.
This code will be used for surveys, consent forms, refusal forms,
and correspondence letters to match participants to the correct
family unit and maintain the study’s internal validity. The PI
and coordinators will keep logs with these codes. The coding
key will be kept in a password-protected computer file and will
be available to the PI, members of the Swiss Cancer Genetic
Predisposition Cascade Screening Consortium, and key
personnel. The code will be broken only to avert an immediate
risk to the health of the person, in cases of withdrawal from the
study, or when there is a legal basis.
All study data will be collected and stored in a secure database
and handled by the data management team from the Clinical
Trials Unit, University Hospital, Basel (CTU Basel). The online
survey will be implemented using LimeSurvey, installed on a
separate server, and exclusively used for the study. Lime Survey
is an established app to perform online surveys. The system
(server and data) is integrated in a regular backup process. Data
transfer from and to the Web-based survey system are encrypted
using secure sockets layer/transport layer security (SSL/TLS).
The secure database will be used for data collection and to track
returned surveys. Data entered for paper/pencil surveys will be
double-checked for accuracy. The usability of the paper/pencil
or online survey will be assessed based on number of individuals
who choose either mode, percent of missing data, etc. Many
items are parts of multi-item scales and are anticipated to
correlate with each other. The reliability of these scales will be
tested using principal component analyses and Cronbach alpha
coefficients. Scales with alpha≥.71 will be used. On completion
of approximately 30 surveys, scale psychometrics will be
examined. For any given scale that shows less than required
psychometric properties (ie, Cronbach alpha<.71 and factor
analysis indicates item loadings <10% compared to item
loadings in the original scale), a revision of the translated scale
will be undertaken. This will allow comparisons of scale
reliability based on delivery mode and will establish whether
the survey can be administered interchangeably.
Health-related and personal data collected for the CASCADE
study are confidential; coding will safeguard participants’
confidentiality. All study documents will be archived in the PI’s
office. Site-related documents will be archived at the office of
each medical director. Administrative data are accessible only
by authorized personnel and data managers from CTU Basel.
Direct access to documents will be permitted for monitoring,
audits, or inspections. Ethics committee members, members of
the Swiss Cancer Genetic Predisposition Cascade Screening
Consortium, the statistician, and key personnel will have access
to project plan, dataset, statistical code, etc, during and after the
study (publication, dissemination). Paper/pencil surveys will
be stored in a separate research office in the PI’s building for 5
years and then destroyed by shredding. Once all data have been
collected, the complete dataset and survey setup will be exported
by CTU Basel and transferred to the PI and the statistician via
a secure channel. The survey system (including database) will
be purged after the end of the study. The PI will archive the
electronic data for a minimum of 10 years.
Outcomes
Table 2 [73-89] describes primary outcomes for index cases
and relatives and the scales used to assess them. The feasibility
of establishing a family-based registry will be assessed using
the number of mutation-harboring families associated with
HBOC and LS from each clinical site, the number of relatives
identified from pedigrees and family history, index cases’
response rate to the CASCADE survey, the number of relatives
each index case is willing to invite, relatives’ response rate to
the CASCADE survey, and the willingness of index cases and
relatives to be contacted once a year for 5 years. Additional
outcomes include assessing acceptance rates of paper/pencil
and online platform and quality of data (eg, percent missing
values).
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Table 2. Scales used in the CASCADE survey.
RelativesIndex caseScaleConcepts
√√Age, gender, education, employment status (previously used) [73]Demographics
Health history
√√Chronic conditions associated with mobility, cardiovascular disease, diabetes,
anxiety, depression
Self-reported list (yes/no) (previously used) [73]
Comorbidities
√√Risk factors associated with the Gail model [74,75]
Self-reported
Reproductive history (females)
√√Self-reported (previously used) [76]Alcohol, tobacco, physical activity
Cancer-related
√√Type of cancer, age of onset
Self-reported list (previously used) [73]
Cancer diagnoses
√√Surgeries associated with HBOC & LS
Prophylactic surgeries
Self-reported (previously used) [29]
Surgery
√√Surveillance for cancers associated with HBOC & LS
Surveillance for common cancers
Investigating tool developed per the American Society of Clinical Oncology
guidelines [77] (previously used) [73]
Surveillance behaviors
√√Barriers & facilitators (previously used) [73]
Coordination of medical care (multiple choices)
High out-of-pocket costs (yes/no)
√√Family history in 1st and 2nd degree relatives & 1st cousins – type of cancer,
age of onset (previously used) [73]
Family history
Psychosocial needs
√√Concerns About Recurrence Scale [78]
4 items, 7-point Likert scale
Fear of cancer recurrence
√√Perceived Risk for Developing Cancer [79]
1 item, 10 points with verbal anchors
Perceived cancer risk
√Decisional Conflict associated with genetic testing [80]
16 items, 7-point Likert scale
Decisional conflict
√Decisional Regret associated with genetic testing [81]
5 items, 7-point Likert scale
Decisional regret
√√Brief Cope [82]
25 items, 7-point Likert scale
Coping with stressful events
√√Self-efficacy dealing with cancer [83]
14 items, 7-point Likert scale
Self-efficacy
√Self-efficacy – use genetic services (counseling & testing) [83]
1 item, 7-point Likert scale
√√Breast & Ovarian Cancer Risk Factor Knowledge Index [84,85]
17 items (True, False, Don’t Know)
Knowledge
√√Knowledge of Breast Cancer Genetics Scale [70]
12 items (True, False, Don’t Know)
√√LS Risk Factors & Inheritance
Investigator developed
19 items (True, False, Don’t Know)
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√Need for physician communication about mutation
Investigator developed
10 items, 7-point Likert scale
Physician
√√Mutuality & Interpersonal Sensitivity [86]
15 items, 7-point Likert scale
Family
√√Family Support in Illness [73,87]
10 items, 7-point Likert scale
√Communication with children & relatives about mutation
(previously used) [29]
17 items (multiple choice)
Genetic services
√√Barriers & facilitators (previously used) [29,88]
11 items, 7-point Likert scale &
22 items (multiple choice)
Genetic services
√√Had genetic testing (yes/no)
Self-reported
Genetic testing
√Source & involvement (previously used) [29]
16 items (multiple choice)
Referral
√√SF-12 [89]
Physical component & Mental component
Quality of Life
Data Analyses
Selection bias will be minimized by random selection of
mutation-harboring families in each clinical site from three
linguistic regions of Switzerland. Stratification will ensure
selection of an equal proportion of index cases from clinical
sites that offer genetic services for both syndromes. The study
will try to recruit all index cases from clinical sites including
fewer than 100 mutation-harboring HBOC/LS families to ensure
a representative sample.
All statistical analyses will be conducted in licensed software
packages, including Microsoft Excel, SPSS (IBM), and R. For
all statistical tests, significance will be set at two-sided
alpha=.05. Data values will be examined for legality (within
appropriate range) using histograms and box plots and corrected
when possible. Descriptive analyses will include calculating
means, standard deviations, frequencies, and percentages of
variables and participant descriptors. Bivariate analyses (Pearson
correlations, chi-square test for differences in proportions, and
t test for differences in means) will assess associations between
demographics and clinical characteristics. Regression analyses
will incorporate generalized estimating equations for pairing
index cases with their relatives and explore to what extent
predictors are in direct, mediating, or moderating relationship
to an outcome.
The following comparisons will take place: between index cases
and relatives, between HBOC and LS, between men and women,
cancer patients versus cancer-free individuals, participants with
children versus those with no children, between different age
groups and different cancer diagnoses. Data from participants
who withdraw will be kept in the study to ensure the internal
validity of the study. Missing data from multi-item scales will
be addressed with multiple imputations using R software if they
exceed 5% of observations and if they are less than 25% for
each specific scale. Scale reliability will be assessed with
Cronbach alpha and principle component analyses. Deviations
from the planned analyses are not foreseen. The study statistician
will review and approve any deviations from the original
statistical plan if necessary.
Narrative data from focus groups will be recorded and
transcribed verbatim to allow data management and content
examination. Thematic analyses to inductively classify data in
concepts and categories, as these emerge through an interpretive
process, will be carried out under the guidance of the qualitative
methodologist [90]. Focus group participants will be shown a
prototype of a family-based intervention as a PowerPoint
presentation. Then they will be asked if they like the
intervention, if they find it useful, and how it can be improved.
Acceptability of the intervention will be assessed with a short
survey using 7-point Likert-type items (1=Low to 7=High)
asking overall satisfaction with the content, format and
appearance of the program, and whether it can help with family
communication, coping, and decision making. The survey
assesses six acceptability items: ease of use, clarity, appropriate
length, appropriate level of detail, able to hold interest, and
satisfaction.
Results
This study is currently recruiting participants.
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Cancer predisposition cascade genetic screening combines
personalized medicine and public health. Once a mutation carrier
for HBOC or Lynch syndrome is identified, evidence-based
interventions are available that can reduce the risk of adverse
health outcomes in entire cohorts of relatives [91]. This approach
is cost-effective for Tier 1 genetic conditions, leading to reduced
medical and insurance coverage costs (eg, treatment and
hospitalization expenses) [92-94]. Cascade screening for FH
applied in the Netherlands identified thousands of mutation
carriers for the disorder and has been subsidized by the Dutch
government since 2015 [95,96]. Similar programs for FH have
also been implemented in Scotland and Wales [97,98].
Availability of genetic testing created an increasing demand for
coordination of health care services and risk communication
among index cases and relatives. Knowledge of hereditary risk
can serve as an information tool to reduce cancer morbidity and
mortality. This necessitates the establishment of family-based
registries that systematically record genetic information.
Currently, this information is fragmented and dispersed across
Swiss clinical sites. The establishment of high-risk clinics would
allow synergistic approaches in cancer surveillance and medical
care offered to these families. Effective data sharing and
dissemination across disciplines is mandatory for increasing the
impact of genetic screening, ensure resource allocation, and
facilitate health care policy and decision making.
Conclusion
CASCADE study will promote multidisciplinary research in
public health genetics at the cutting edge of medicine with strong
translational application. This has significant potential to
enhance the development of high-quality comprehensive support
systems to improve use of cancer genetic services and facilitate
patient involvement in health care decisions. The long-term
outcome of this program is the development and implementation
of new models for systematic surveillance and detection of
individuals at risk for hereditary cancer in Switzerland.
Immediate outcomes are the assessment of current use of cancer
genetic services and evaluation of the public health impact of
HBOC and LS. The CASCADE study will document the needs
of mutation-harboring families, including barriers and facilitators
to accessing cancer genetic services, and will promote use of
family history for genetic risk assessment. The study will also
provide information for the acceptability of an intervention that
will potentially increase genetic literacy, expand understanding
of health care technologies, and reduce HBOC- and LS-related
morbidity and mortality in Switzerland.
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